Free Trial

Ampio Pharmaceuticals Q4 2023 Earnings Report

Ampio Pharmaceuticals logo
$0.0026 0.00 (0.00%)
As of 01/21/2025 03:00 PM Eastern

Ampio Pharmaceuticals EPS Results

Actual EPS
-$2.48
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Ampio Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Ampio Pharmaceuticals Announcement Details

Quarter
Q4 2023
Time
N/A

Conference Call Resources

Ampio Pharmaceuticals Earnings Headlines

Bill Gates’ is about to mint millionaires (again) with Stargate.
This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrough so advanced, it’s going to make ChatGPT look like VHS. But what’s even more unbelievable? I believe it’ll make Nvidia’s meteoric rise look like a backyard bottle rocket.
Ampio Pharmaceuticals, Inc. (AMPE)
See More Ampio Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Ampio Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ampio Pharmaceuticals and other key companies, straight to your email.

About Ampio Pharmaceuticals

Ampio Pharmaceuticals (NYSE:AMPE), a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado.

View Ampio Pharmaceuticals Profile

More Earnings Resources from MarketBeat